Altogether, we suggest that treatment with LSL60101 alters the expression of genes associated with neuroinflammation processes in the 5XFAD model, which could be dependent on the NF-κβ pathway, reinforcing the role of this pathway as a therapeutic target for AD [35]. This evidence concerns the gene NFKB1 and Alzheimer disease.